| Literature DB >> 32534579 |
Åsa Degerstedt1, Hassan Alinaghizadeh2, Carina A Thorstensson3,4, Christina B Olsson5,6,7.
Abstract
BACKGROUND: Self-efficacy is considered a core component in self-management. However, there is a lack of knowledge about the association between self-efficacy and health-related outcomes in osteoarthritis. The aim of this study was to investigate whether self-efficacy at baseline was associated with change over time in pain and physical activity after a supported osteoarthritis self-management programme.Entities:
Keywords: Education; Exercise; Hip; Knee; Primary health care
Year: 2020 PMID: 32534579 PMCID: PMC7293780 DOI: 10.1186/s12891-020-03407-x
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Fig. 1Disposition of the supported osteoarthritis self-management program for patients. OA = osteoarthritis; PT = physiotherapist
Demographic and clinical characteristics at baseline (n = 3266)
| Variable | Total | Low SE pain ≤62 | High SE pain > 62 | Low SE OS ≤68 | High SE OS > 68 | ||
|---|---|---|---|---|---|---|---|
| baseline | 48.48 (18.48) | 52.96 (16.86) | 43.46 (18.88) | < 0.01c* | 52.60 (17.46) | 43.86 (18.48) | < 0.01c* |
| 3 months | 37.68 (19.68) | 42.35 (19.11) | 32.56 (19.00) | < 0.01c* | 42.17 (19.06) | 32.92 (19.28) | < 0.01c* |
| 1 year | 39.97 (20.34) | 44.24 (19.26) | 35.23 (20.45) | < 0.01c* | 43.96 (19.73) | 35.54 (20.19) | < 0.01c* |
| baseline | 5.22 (2.05) | 5.12 (2.15) | 5.33 (1.92) | < 0.01c* | 4.99 (2.17) | 5.47 (1.87) | < 0.01c* |
| 3 months | 5.45 (1.76) | 5.40 (1.81) | 5.50 (1.70) | 0.11c | 5.29 (1.84) | 5.60 (1.65) | < 0.01c* |
| 1 year | 5.14 (1.91) | 5.06 (1.99) | 5.24 (1.81) | < 0.01*c | 4.99 (2.01) | 5.31 (1.78) | < 0.01c* |
| mean (SD) | 64.73 (9.22) | 66.33 (9.30) | 64.01 (9.08) | < 0.01*c | 65.42 (9.57) | 63.90 (8.74) | < 0.01c* |
| min | 27–93 | 32–93 | 27–89 | 32–93 | 27–88 | ||
| male | 923 (28.26) | 495 (28.98) | 420 (27.50) | 0.35d | 465 (27.26) | 442 (29.33) | 0.19d |
| female | 2343 (71.74) | 1213 (71.5) | 1107 (72.50) | 1241 (72.74) | 1065 (70.67) | ||
| cohabiting | 2419 (74.29) | 1235 (72.48) | 1161 (76.23) | 0.01d* | 1208 (70.98) | 1168 (77.66) | < 0.01d* |
| living alone | 837 (25.71) | 469 (27.52) | 362 (23.77) | 494 (29.02) | 336 (22.34) | ||
| yes | 3013 (92.37) | 1569 (91.92) | 1419 (92.99) | 0.25d | 1559 (91.44) | 1410 (93.63) | 0.02d* |
| no | 249 (7.63) | 138 (8.08) | 107 (7.01) | 146 (8.56) | 96 (6.37) | ||
| compulsory school | 1213 (37.37) | 714 (42.02) | 484 (31.86) | < 0.01d* | 710 (41.89) | 478 (31.85) | < 0.01d* |
| upper secondary school | 1118 (34.44) | 601 (35.37) | 514 (33.84) | 594 (35.04) | 512 (34.11) | ||
| university | 915 (28.19) | 384 (22.60) | 521 (34.30) | 391 (23.07) | 511 (34.04) | ||
| underweight < 18.5 | 64 (2.01) | 34 (2.04) | 27 (1.82) | 0.04d* | 33 (1.99) | 27 (1.84) | < 0.01d* |
| normal weight 18.5 | 877 (27.59) | 425 (25.56) | 442 (29.76) | 426 (25.72) | 436 (29.66) | ||
| overweight 25 | 1338 (42.09) | 706 (42.45) | 618 (41.62) | 678 (40.94) | 636 (43.27) | ||
| obese ≥30 | 900 (28.31) | 498 (29.95) | 398 (26.80) | 519 (31.34) | 371 (25.24) | ||
| hip | 894 (27.37) | 498 (29.16) | 388 (25.41) | 0.02d* | 492 (28.84) | 388 (25.75) | 0.05d |
| knee | 2372 (72.63) | 1210 (70.84) | 1139 (74.54) | 1214 (71.16) | 1119 (74.25) | ||
| no | 1459 (45.13) | 701 (41.55) | 746 (49.18) | < 0.01d* | 727 (43.12) | 713 (47.63) | 0.01d* |
| yes | 1774 (54.87) | 986 (58.45) | 771 (50.82) | 959 (56.88) | 784 (52.37) | ||
| no | 539 (16.70) | 176 (10.44) | 357 (23.58) | < 0.01d* | 178 (10.58) | 352 (23.53) | < 0.01d* |
| yes | 2689 (83.3) | 1510 (88.1) | 1157 (76.42) | 1505 (89.42) | 1144 (76.47) | ||
Demographic and clinical characteristics at baseline for the total cohort (n = 3266) and separately for the groups of participants with low vs high self-efficacy for pain management and low vs high self-efficacy for management of other symptoms
SD standard deviation, SE pain self-efficacy for pain management, SE OS self-efficacy for management of other symptoms, VAS visual analogue scale
aMeasured using a VAS from 0 to 100; bdays per week of being physically active for ≥30 min; ct-test; d chi-square test
*p-value< 0.05
Fig. 2Flow chart of the study, showing the number of participants that answered at baseline and at follow-up. SE = self-efficacy; SE pain = self-efficacy for pain management; SE OS = self-efficacy for management of other symptoms
Self-efficacy for pain at baseline, association with pain and physical activity at the follow-ups
| Pain | Physical activity | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted modelc | Adjusted modelc | Unadjusted modelc | Adjusted modelc | |||||||
| LSM ± SE | Effect size ( | LSM ± SE | LSM ± SE | Effect size ( | LSM ± SE | |||||
| 31.67 ± 0.81 | < 0.01* | 5.27 ± 0.15 | < 0.01* | |||||||
| < 0.01* | < 0.01* | |||||||||
| 47.98 ± 0.40 | 4.92 ± 0.08 | |||||||||
| 37.07 ± 0.41 | 5.15 ± 0.08 | |||||||||
| 37.47 ± 0.43 | 4.86 ± 0.08 | |||||||||
| < 0.01* | < 0.01* | |||||||||
| 44.26 ± 0.40 | 4.90 ± 0.08 | |||||||||
| 37.43 ± 0.40 | 5.05 ± 0.07 | |||||||||
| < 0.01* | 0.002 | < 0.01* | < 0.01 | 0.010 | < 0.01* | |||||
| 42.81 ± 0.28 | 40.25 ± 0.42 | 4.98 ± 0.03 | 4.73 ± 0.05 | |||||||
| 43.99 ± 0.18 | 41.45 ± 0.38 | 5.37 ± 0.05 | 5.07 ± 0.04 | |||||||
| 0.05 | 0.001 | 0.06 | < 0.01 | 0.003 | < 0.01* | |||||
| 44.80 ± 0.81 | 41.21 ± 0.72 | 4.63 ± 0.16 | 4.54 ± 0.08 | |||||||
| 43.77 ± 0.16 | 41.09 ± 0.32 | 5.27 ± 0.03 | 5.06 ± 0.04 | |||||||
| 42.95 ± 0.39 | 40.26 ± 0.43 | 5.32 ± 0.08 | 5.10 ± 0.05 | |||||||
| < 0.01* | 0.002 | < 0.01* | 0.08 | 0.001 | 0.10 | |||||
| 48.26 ± 0.53 | 42.61 ± 0.52 | 5.10 ± 0.10 | 4.79 ± 0.06 | |||||||
| 43.29 ± 0.15 | 39.09 ± 0.33 | 5.27 ± 0.03 | 5.01 ± 0.04 | |||||||
| < 0.01* | 0.001 | 0.13 | 0.04 | 0.001 | 0.08 | |||||
| 43.35 ± 0.17 | 40.65 ± 0.39 | 5.30 ± 0.03 | 4.90 ± 0.05 | |||||||
| 44.47 ± 0.28 | 41.05 ± 0.42 | 5.36 ± 0.05 | 4.89 ± 0.05 | |||||||
| < 0.01* | 0.001 | < 0.01* | 0.09 | 0.000 | 0.15 | |||||
| 44.41 ± 0.24 | 41.81 ± 0.42 | 5.32 ± 0.04 | 4.92 ± 0.05 | |||||||
| 44.59 ± 0.25 | 42.06 ± 0.40 | 5.18 ± 0.05 | 4.88 ± 0.05 | |||||||
| 41.39 ± 0.28 | 38.68 ± 0.42 | 5.27 ± 0.05 | 4.89 ± 0.05 | |||||||
| < 0.01* | 0.001 | < 0.01* | 0.81 | 0.000 | 0.79 | |||||
| 41.36 ± 0.22 | 39.00 ± 0.40 | 5.27 ± 0.04 | 4.89 ± 0.05 | |||||||
| 45.86 ± 0.21 | 42.70 ± 0.40 | 5.25 ± 0.04 | 4.90 ± 0.05 | |||||||
| < 0.01* | 0.001 | < 0.01* | 0.08 | 0.001 | 0.61 | |||||
| 45.36 ± 0.27 | 42.68 ± 0.42 | 5.32 ± 0.04 | 4.89 ± 0.05 | |||||||
| 42.94 ± 0.18 | 39.02 ± 0.39 | 5.25 ± 0.02 | 4.90 ± 0.05 | |||||||
| < 0.01* | 0.025 | < 0.01* | < 0.01 | 0.002 | 0.03* | |||||
| 32.21 ± 0.36 | 34.86 ± 0.45 | 5.46 ± 0.05 | 4.84 ± 0.04 | |||||||
| 45.81 ± 0.16 | 46.82 ± 0.37 | 5.23 ± 0.02 | 4.95 ± 0.05 | |||||||
| < 0.01* | 0.008 | 0.05 | < 0.01 | 0.054 | < 0.01* | |||||
| 43.21 ± 0.92 | 40.40 ± 0.82 | 5.31 ± 0.14 | 4.74 ± 0.10 | |||||||
| 40.61 ± 0.29 | 38.83 ± 0.38 | 5.57 ± 0.04 | 5.28 ± 0.05 | |||||||
| 43.06 ± 0.22 | 40.45 ± 0.36 | 5.33 ± 0.03 | 5.00 ± 0.04 | |||||||
| 47.40 ± 0.28 | 43.70 ± 0.39 | 4.86 ± 0.04 | 4.56 ± 0.05 | |||||||
Self-efficacy for pain management at baseline, and association with pain and physical activity at the follow-ups. Estimated least squares means from unadjusted and adjusted models for pain and physical activity using self-efficacy for pain management as a fixed factor in all models. Effect sizes are from the unadjusted model for each demographic and clinical characteristic
BMI body mass index, LSM least squares means, ref. reference category, SE standard error
aMeasured using a VAS from 0 to 100; bdays per week of being physically active for ≥30 min; cMixed linear model analysis with a restricted maximum likelihood method; deffect size interpreted according to Cohen’s guidelines: ≥0.02 = small; ≥0.15 = medium; ≥0.35 = large [35]
*p-value< 0.05
Self-efficacy for other symptoms at baseline, association with pain and physical activity at the follow-ups
| Pain | Physical activity | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted modelc | Adjusted modelc | Unadjusted modelc | Adjusted modelc | |||||||
| LSM ± SE | p-value | Effect size ( | LSM ± SE | LSM ± SE | p-value | Effect size ( | LSM ± SE | p-value | ||
| 27.91 ± 1.39 | < 0.01* | 5.39 ± 0.09 | < 0.01* | |||||||
| < 0.01* | < 0.01* | |||||||||
| 45.14 ± 0.73 | 4.84 ± 0.05 | |||||||||
| 34.51 ± 0.74 | 5.07 ± 0.05 | |||||||||
| 36.67 ± 0.73 | 4.80 ± 0.05 | |||||||||
| < 0.01* | < 0.01* | |||||||||
| 41.76 ± 0.71 | 4.72 ± 0.05 | |||||||||
| 35.78 ± 0.71 | 5.08 ± 0.05 | |||||||||
| < 0.01* | 0.001 | < 0.01* | < 0.01* | 0.003 | < 0.01* | |||||
| 40.43 ± 0.51 | 37.63 ± 0.75 | 4.98 ± 0.03 | 4.73 ± 0.05 | |||||||
| 42.86 ± 0.32 | 39.92 ± 0.69 | 5.32 ± 0.02 | 5.08 ± 0.04 | |||||||
| 0.07 | 0.001 | < 0.01* | < 0.01* | 0.002 | < 0.01* | |||||
| 39.13 ± 1.62 | 37.27 ± 1.28 | 4.68 ± 0.09 | 4.54 ± 0.08 | |||||||
| 42.39 ± 0.29 | 40.14 ± 0.58 | 5.37 ± 0.02 | 5.12 ± 0.05 | |||||||
| 41.31 ± 0.79 | 38.92 ± 0.79 | 5.37 ± 0.05 | 5.11 ± 0.05 | |||||||
| < 0.01* | 0.002 | < 0.01* | < 0.01* | 0.001 | < 0.01* | |||||
| 47.96 ± 0.98 | 41.13 ± 0.92 | 4.98 ± 0.06 | 4.80 ± 0.06 | |||||||
| 41.71 ± 0.28 | 36.41 ± 0.61 | 5.25 ± 0.02 | 5.01 ± 0.04 | |||||||
| 0.22 | 0.001 | 0.96 | 0.32 | 0.001 | 0.97 | |||||
| 41.99 ± 0.31 | 38.78 ± 0.70 | 5.21 ± 0.02 | 4.90 ± 0.05 | |||||||
| 42.75 ± 0.54 | 38.76 ± 0.74 | 5.25 ± 0.03 | 4.90 ± 0.05 | |||||||
| < 0.01* | 0.001 | < 0.01* | 0.01* | 0.000 | 0.10 | |||||
| 42.92 ± 0.44 | 39.70 ± 0.74 | 5.26 ± 0.03 | 4.94 ± 0.05 | |||||||
| 43.29 ± 0.46 | 40.17 ± 0.72 | 5.16 ± 0.03 | 4.88 ± 0.05 | |||||||
| 39.72 ± 0.51 | 36.45 ± 0.76 | 5.26 ± 0.03 | 4.88 ± 0.05 | |||||||
| < 0.01* | 0.002 | < 0.01* | 0.47 | −0.000 | 0.64 | |||||
| 39.39 ± 0.40 | 36.89 ± 0.72 | 5.23 ± 0.02 | 4.90 ± 0.05 | |||||||
| 44.42 ± 0.36 | 40.66 ± 0.71 | 5.21 ± 0.02 | 4.91 ± 0.05 | |||||||
| < 0.01* | 0.000 | < 0.01* | 0.15 | 0.000 | 0.80 | |||||
| 43.51 ± 0.52 | 40.42 ± 0.75 | 5.26 ± 0.03 | 4.90 ± 0.05 | |||||||
| 41.67 ± 0.32 | 37.13 ± 0.69 | 5.21 ± 0.02 | 4.91 ± 0.05 | |||||||
| 0.025 | < 0.01* | < 0.01* | 0.001 | 0.08 | ||||||
| 31.08 ± 0.64 | < 0.01* | 32.87 ± 0.80 | 5.36 ± 0.04 | 4.94 ± 0.05 | ||||||
| 44.41 ± 0.28 | 44.67 ± 0.67 | 5.20 ± 0.02 | 4.87 ± 0.04 | |||||||
| < 0.01* | 0.007 | < 0.01* | < 0.01* | 0.052 | < 0.01* | |||||
| 41.29 ± 1.92 | 37.60 ± 1.59 | 5.08 ± 0.10 | 4.76 ± 0.10 | |||||||
| 39.41 ± 0.51 | 37.30 ± 0.63 | 5.59 ± 0.03 | 5.27 ± 0.04 | |||||||
| 41.26 ± 0.42 | 38.18 ± 0.63 | 5.26 ± 0.03 | 5.00 ± 0.04 | |||||||
| 46.59 ± 0.51 | 42.01 ± 0.67 | 4.84 ± 0.03 | 4.58 ± 0.05 | |||||||
Self-efficacy for management of other symptoms at baseline, and association with pain and physical activity at the follow-ups. Estimated least squares means from unadjusted and adjusted models for pain and physical activity using self-efficacy for management of other symptoms as a fixed factor in all models. Effect sizes are from the unadjusted model for each demographic and clinical characteristic
BMI body mass index, LSM least squares means, ref. reference category, SE standard error
aMeasured using a VAS from 0 to 100; bdays per week of being physically active for ≥30 min; cMixed linear model analysis with a restricted maximum likelihood method; deffect size interpreted according to Cohen’s guidelines: ≥0.02 = small; ≥0.15 = medium; ≥0.35 = large [35]
*p-value< 0.05
Fig. 3Least Squares Means (LS-mean) adjusted for all confounders in mixed linear models for Pain (VAS scale) and Physical activity (days per week being physically active for at least 30 min) at baseline and follow-ups for patients with high and low self-efficacy for pain (SE pain) and other symptoms (SE other symptoms) at baseline